GlassScriptPhysician profile
Gerald A Sparks
NPI 1770533507
$2,844.83
in general payments reported to CMS, 2019-2025
35 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $128 · 2021: $775 · 2022: $513 · 2023: $230 · 2024: $413 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $504.10 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $289.62 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $262.06 | 2020-2025 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $222.25 | 2019-2023 | Verquvo, Belsomra |
| Astrazeneca Pharmaceuticals LP | $135.24 | 2020-2025 | Airsupra, Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $125.46 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.23 | 2022-2025 | |
| Amgen INC. | $103.66 | 2019-2025 | Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.57 | 2022-2025 | Xifaxan |
| Amarin Pharma, INC. | $87.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $82.81 | 2021-2023 | |
| Pfizer INC. | $81.25 | 2019-2021 | |
| Glaxosmithkline, LLC. | $80.56 | 2019-2024 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $65.92 | 2022-2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $61.64 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.69 | 2019-2021 | |
| Dexcom, INC. | $51.71 | 2021-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $42.64 | 2023-2024 | Venaseal, Kyphon Express II Kyphopak Tray |
| Lundbeck LLC | $38.01 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $34.82 | 2023-2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $33.58 | 2024 | Nuedexta |
| Avanir Pharmaceuticals, INC. | $32.26 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $29.11 | 2019 | |
| Inspire Medical Systems, INC. | $28.65 | 2024 | Inspire |
| Insulet Corporation | $26.49 | 2025 | Omnipod |
| Almatica Pharma LLC | $21.79 | 2025 | Loreev Xr |
| Boston Scientific Corporation | $21.31 | 2025 | Watchman Access System |
| Axsome Therapeutics, INC. | $19.37 | 2025 | Auvelity |
| Shire North American Group INC | $16.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.62 | 2020 | |
| Mylan Specialty L.P. | $15.19 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.78 | 2022 | |
| Allergan, INC. | $13.45 | 2020 | |
| Phathom Pharmaceuticals, INC. | $11.14 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Sparks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.